- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing the sequencing of Bruton tyrosine kinase (BTK) inhibitors in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treatment while considering other financial factors like insurance coverage, copays, and total out-of-pocket costs that impact patient access and treatment decisions.
EP: 1.Fixed-Duration Options for CLL
EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study
EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
EP: 4.Sequencing Considerations in Relapsed/Refractory CLL
EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL
EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
EP: 8.Switching Between BTK Inhibitors in CLL
EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity
EP: 10.Opportunities for Easing BTK Inhibitor Switches
EP: 11.Reflections on 2024’s Progress in R/R CLL
Video content above is prompted by the following:
- With ibrutinib on the negotiated drug price list under the IRA, how might cost considerations influence first-line BTK inhibitor selection and subsequently shape second-line and beyond treatment choices in R/R CLL?
- Beyond the IRA, what role do broader economic factors, such as insurance coverage and out-of-pocket costs, play in treatment selection for patients with R/R CLL requiring BTK inhibitors?
Survey Explores Needs of Patients With DMD, BMD Transitioning to Adulthood
February 28th 2025Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), but those who had more siblings reported being more ready to transition to adult life.
Read More
Falls, Balance Issues Signal Higher ICANS Risk in NHL
February 28th 2025Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Read More
